1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Clinically Isolated CNS Demyelinating Syndrome in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Barnes, GN; Cai, J; Chu, T; Kong, M; Shields, CB; Shields, LBE; Tian, Z; Wang, Y; Zhang, YP; Zhu, Q | 1 |
1 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Clinically Isolated CNS Demyelinating Syndrome
Article | Year |
---|---|
Platelet-Activating Factor Deteriorates Lysophosphatidylcholine-Induced Demyelination Via Its Receptor-Dependent and -Independent Effects.
Topics: Animals; Cerebellum; Cytokines; Demyelinating Diseases; Gene Deletion; Inflammation Mediators; Lysophosphatidylcholines; Mice, Inbred C57BL; Mice, Knockout; Microglia; Myelin Basic Protein; Neurofilament Proteins; Platelet Activating Factor; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Transcription, Genetic | 2020 |